Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib hydrochloride + irinotecan
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib hydrochloride + irinotecan is a combination therapy consisting of anlotinib, a multi-targeted tyrosine kinase inhibitor, and irinotecan, a topoisomerase I inhibitor. Anlotinib inhibits angiogenesis and tumor cell proliferation by targeting multiple receptor tyrosine kinases including VEGFR, FGFR, PDGFR, and c-Kit. Irinotecan interferes with DNA replication in cancer cells by inhibiting topoisomerase I. This combination has been investigated primarily as a second-line treatment for advanced or metastatic cancers such as colorectal cancer (mCRC), esophageal squamous cell carcinoma (ESCC), and Ewing sarcoma after failure of first-line therapies. Clinical studies have shown that the regimen demonstrates promising anti-tumor activity with manageable safety profiles in these settings[3][4][6].
- Other names
- anlotinib plus irinotecananlotinib and irinotecan
02
Targets
FGFR3 (Fibroblast growth factor receptor 3)TOP1 (DNA Topoisomerase I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on anlotinib hydrochloride + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib hydrochloride + irinotecan.